Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Study protocol

Epidemiological study of prostate cancer (EPICAP): a population-based case–control study in France

Authors: Florence Menegaux, Antoinette Anger, Hasina Randrianasolo, Claire Mulot, Pierre Laurent-Puig, François Iborra, Jean-Pierre Bringer, Benoit Leizour, Rodolphe Thuret, Pierre-Jean Lamy, Xavier Rébillard, Brigitte Trétarre, EPICAP Study Group

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

Prostate cancer is the most common cancer in male in most Western countries, including France. Despite a significant morbidity and mortality to a lesser extent, the etiology of prostate cancer remains largely unknown. Indeed, the only well-established risk factors to date are age, ethnicity and a family history of prostate cancer. We present, here, the rationale and design of the EPIdemiological study of Prostate CAncer (EPICAP), a population-based case–control study specifically designed to investigate the role of environmental and genetic factors in prostate cancer. The EPICAP study will particularly focused on the role of circadian disruption, chronic inflammation, hormonal and metabolic factors in the occurrence of prostate cancer.

Methods/Design

EPICAP is a population-based case–control study conducted in the département of Hérault in France. Eligible cases are all cases of prostate cancers newly diagnosed in 2012-2013 in men less than 75 years old and residing in the département of Hérault at the time of diagnosis. Controls are men of the same age as the cases and living in the département of Hérault, recruited in the general population.
The sample will include a total of 1000 incident cases of prostate cancer and 1000 population-based controls over a 3-year period (2012-2014).
The cases and controls are face-to-face interviewed using a standardized computed assisted questionnaire. The questions focus primarily on usual socio-demographic characteristics, personal and family medical history, lifestyle, leisure activities, residential and occupational history. Anthropometric measures and biological samples are also collected for cases and controls.

Discussion

The EPICAP study aims to answer key questions in prostate cancer etiology: (1) role of circadian disruption through the study of working hours, chronotype and duration/quality of sleep, (2) role of chronic inflammation and anti-inflammatory drugs, (3) role of hormonal and metabolic factors through a detailed questionnaire, (4) role of individual genetic susceptibility of genes involved in biological pathways of interest. The EPICAP study will also allow us to study prognostic factors and tumor aggressiveness.
Taken together, the EPICAP study will provide a comprehensive framework to go further in the understanding of prostate cancer occurrence and its prognosis.
Appendix
Available only for authorised users
Literature
1.
InVS: Projections de l’incidence et de la mortalité par cancer en France en 2011. Rapport technique. 2011, Saint-Maurice: Institut de veille sanitaire
2.
Hsing AW, Tsao L, Devesa SS: International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000, 85: 60-67. 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO;2-B.CrossRefPubMed
3.
Bostwick DG, Burke HB, Djakiew D, Euling S, Ho S, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B: Human prostate cancer risk factors. Cancer. 2004, 101 (10 Suppl): 2371-2490.CrossRefPubMed
4.
5.
Hsing AW, Devesa SS: Trends and patterns of prostate cancer: what do they suggest?. Epidemiol Rev. 2001, 23: 3-13. 10.1093/oxfordjournals.epirev.a000792.CrossRefPubMed
6.
Hsing AW, Sakoda LC, Chua S: Obesity, metabolic syndrome, and prostate cancer. Am J Clin Nutr. 2007, 86: s843-s857.PubMed
7.
Lee J, Demissie K, Lu S-E, Rhoads GG: Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control. 2007, 14: 78-85.PubMed
8.
Stevens RG, Hansen J, Costa G, Haus E, Kauppinen T, Aronson KJ, Castaño-Vinyals G, Davis S, Frings-Dresen MHW, Fritschi L, Kogevinas M, Kogi K, Lie J-A, Lowden A, Peplonska B, Pesch B, Pukkala E, Schernhammer E, Travis RC, Vermeulen R, Zheng T, Cogliano V, Straif K: Considerations of circadian impact for defining “shift work” in cancer studies: IARC Working Group Report. Occup Environ Med. 2011, 68: 154-162. 10.1136/oem.2009.053512.CrossRefPubMed
9.
Kolstad HA: Nightshift work and risk of breast cancer and other cancers--a critical review of the epidemiologic evidence. Scand J Work Environ Health. 2008, 34: 5-22. 10.5271/sjweh.1194.CrossRefPubMed
10.
Costa G, Haus E, Stevens R: Shift work and cancer - considerations on rationale, mechanisms, and epidemiology. Scand J Work Environ Health. 2010, 36 (2): 163-179. 10.5271/sjweh.2899.CrossRefPubMed
11.
Fritschi L, Glass DC, Heyworth JS, Aronson K, Girschik J, Boyle T, Grundy A, Erren TC: Hypotheses for mechanisms linking shiftwork and cancer. Med Hypotheses. 2011, 77: 430-436. 10.1016/j.mehy.2011.06.002.CrossRefPubMed
12.
Sigurdardottir LG, Valdimarsdottir UA, Fall K, Rider JR, Lockley SW, Schernhammer E, Mucci LA: Circadian disruption, sleep loss, and prostate cancer risk: a systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2012, 21: 1002-1011. 10.1158/1055-9965.EPI-12-0116.CrossRefPubMedPubMedCentral
13.
Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, Miki T, Nakao M, Hayashi K, Suzuki K, Mori M, Washio M, Sakauchi F, Ito Y, Yoshimura T, Tamakoshi A: Prospective cohort study of the risk of prostate cancer among rotating-shift workers: findings from the Japan collaborative cohort study. Am J Epidemiol. 2006, 164: 549-555. 10.1093/aje/kwj232.CrossRefPubMed
14.
Conlon M, Lightfoot N, Kreiger N: Rotating shift work and risk of prostate cancer. Epidemiol. 2007, 18: 182-183. 10.1097/01.ede.0000249519.33978.31.CrossRef
15.
Kubo T, Oyama I, Nakamura T, Kunimoto M, Kadowaki K, Otomo H, Fujino Y, Fujimoto N, Matsumoto T, Matsuda S: Industry-based retrospective cohort study of the risk of prostate cancer among rotating-shift workers. Int J Urol. 2011, 18: 206-211. 10.1111/j.1442-2042.2010.02714.x.CrossRefPubMed
16.
Parent M-É, El-Zein M, Rousseau M-C, Pintos J, Siemiatycki J: Night work and the risk of cancer among men. Am J Epidemiol. 2012, 176: 751-759. 10.1093/aje/kws318.CrossRefPubMed
17.
Buja A, Lange JH, Perssinotto E, Rausa G, Grigoletto F, Canova CMG: Cancer incidence among male military and civil pilots and flight attendants: an analysis on published data. Toxicol Ind Health. 2005, 21: 273-282. 10.1191/0748233705th238oa.CrossRefPubMed
18.
Kakizaki M, Inoue K, Kuriyama S, Sone T, Matsuda-Ohmori K, Nakaya N, Fukudo S, Tsuji I: Sleep duration and the risk of prostate cancer: the Ohsaki Cohort Study. Br J Cancer. 2008, 99: 176-178. 10.1038/sj.bjc.6604425.CrossRefPubMedPubMedCentral
19.
Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow?. Lancet. 2001, 357: 539-545. 10.1016/S0140-6736(00)04046-0.CrossRefPubMed
20.
21.
22.
De Marzo AM, Marchi VL, Epstein JI, Nelson WG: Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999, 155: 1985-1992. 10.1016/S0002-9440(10)65517-4.CrossRefPubMedPubMedCentral
23.
De Marzo AM, Nakai Y, Nelson WG: Inflammation, atrophy, and prostate carcinogenesis. Urol Oncol. 2007, 25: 398-400. 10.1016/j.urolonc.2007.05.007.CrossRefPubMed
24.
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG: Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007, 7: 256-269. 10.1038/nrc2090.CrossRefPubMedPubMedCentral
25.
Dennis LK, Lynch CF, Torner JC: Epidemiologic association between prostatitis and prostate cancer. Urology. 2002, 60: 78-83.CrossRefPubMed
26.
Dennis LK, Dawson DV: Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology. 2002, 13: 72-79. 10.1097/00001648-200201000-00012.CrossRefPubMed
27.
Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson GM, Greenberg RS, Schoenberg JB, Liff J, Schwartz AG, Hoover RN, Fraumeni JF: Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer. 2000, 82: 718-725. 10.1054/bjoc.1999.0986.CrossRefPubMedPubMedCentral
28.
Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP: Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 1999, 41: 127-133. 10.1002/(SICI)1097-0045(19991001)41:2<127::AID-PROS7>3.0.CO;2-H.CrossRefPubMed
29.
Veltri RW, Miller MC, Zhao G, Ng A, Marley GM, Wright GL, Vessella RL, Ralph D: Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology. 1999, 53: 139-147. 10.1016/S0090-4295(98)00455-5.CrossRefPubMed
30.
Shariat SF, Andrews B, Kattan MW, Kim J, Wheeler TM, Slawin KM: Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 2001, 58: 1008-1015. 10.1016/S0090-4295(01)01405-4.CrossRefPubMed
31.
Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, Faruque M, Moses T, Ewing C, Gillanders E, Hu P, Bujnovszky P, Makalowska I, Baffoe-Bonnie A, Faith D, Smith J, Stephan D, Wiley K, Brownstein M, Gildea D, Kelly B, Jenkins R, Hostetter G, Matikainen M, Schleutker J, Klinger K, Connors T, Xiang Y, Wang Z, De Marzo A, et al: Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 2002, 30: 181-184. 10.1038/ng823.CrossRefPubMed
32.
Silverman RH: Implications for RNase L in prostate cancer biology. Biochemistry. 2003, 42: 1805-1812. 10.1021/bi027147i.CrossRefPubMed
33.
Michaud DS, Daugherty SE, Berndt SI, Yeager M, Crawford ED, Hsing A, Huang W-Y, Hayes RB: Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res. 2006, 66: 4525-4530. 10.1158/0008-5472.CAN-05-3987.CrossRefPubMed
34.
Bosetti C, Gallus S, La Vecchia C: Aspirin and cancer risk: an updated quantitative review to 2005. Cancer Causes Control. 2006, 17: 871-888. 10.1007/s10552-006-0033-7.CrossRefPubMed
35.
Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ, Thun M: Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009, 10: 501-507. 10.1016/S1470-2045(09)70035-X.CrossRefPubMed
36.
Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C: Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012, 23: 1403-1415. 10.1093/annonc/mds113.CrossRefPubMed
37.
Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H: Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate. 2000, 42: 73-78. 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G.CrossRefPubMed
38.
Hussain T, Gupta S, Mukhtar H: Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett. 2003, 191: 125-135. 10.1016/S0304-3835(02)00524-4.CrossRefPubMed
39.
Chaudry AA, Wahle KW, McClinton S, Moffat LE: Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer. 1994, 57: 176-180. 10.1002/ijc.2910570208.CrossRefPubMed
40.
DuBois RN: Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?. J Clin Oncol. 2006, 24: 2691-2693. 10.1200/JCO.2006.05.9709.CrossRefPubMed
41.
Mathew P: Inflammatory pathogenesis of prostate cancer and celecoxib. J Clin Oncol. 2010, 28: e197-e198. 10.1200/JCO.2009.27.1098.CrossRefPubMed
42.
Nomura AM, Stemmermann GN, Chyou PH, Henderson BE, Stanczyk FZ: Serum androgens and prostate cancer. Cancer Epidemiol Biomark Prev. 1996, 5: 621-625.
43.
Hsing AW: Hormones and prostate cancer: where do we go from here?. J Natl Cancer Inst. 1996, 88: 1093-1095. 10.1093/jnci/88.16.1093.CrossRefPubMed
44.
Eaton NE, Reeves GK, Appleby PN, Key TJ: Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer. 1999, 80: 930-934. 10.1038/sj.bjc.6690445.CrossRefPubMedPubMedCentral
45.
Hsing AW, Chu LW, Stanczyk FZ: Androgen and prostate cancer: is the hypothesis dead?. Cancer Epidemiol Biomark Prev. 2008, 17: 2525-2530. 10.1158/1055-9965.EPI-08-0448.CrossRef
46.
Roddam AW, Allen NE, Appleby P, Key TJ: Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008, 100: 170-183. 10.1093/jnci/djm323.CrossRefPubMed
47.
Wigle DT, Turner MC, Gomes J, Parent M-E: Role of hormonal and other factors in human prostate cancer. Eur J Toxicol Environ Health Part B, Crit Rev. 2008, 11: 242-259. 10.1080/10937400701873548.CrossRef
48.
Cremers RG, Aben KK, Vermeulen SH, Den Heijer M, Van Oort IM, Kiemeney LA: Androgenic alopecia is not useful as an indicator of men at high risk of prostate cancer. Eur J Cancer. 2010, 46: 3294-3299. 10.1016/j.ejca.2010.05.020.CrossRefPubMed
49.
Ruhayel Y, Giwercman A, Ulmert D, Rylander L, Bjartell A, Manjer J, Berglund G, Giwercman YL: Male infertility and prostate cancer risk: a nested case–control study. Cancer Causes Control. 2010, 21: 1635-1643. 10.1007/s10552-010-9592-8.CrossRefPubMed
50.
Wright JL, Page ST, Lin DW, Stanford JL: Male pattern baldness and prostate cancer risk in a population-based case–control study. Cancer Epidemiol. 2010, 34: 131-135. 10.1016/j.canep.2010.02.003.CrossRefPubMedPubMedCentral
51.
Yassa M, Saliou M, De Rycke Y, Hemery C, Henni M, Bachaud JM, Thiounn N, Cosset JM, Giraud P: Male pattern baldness and the risk of prostate cancer. Ann Oncol. 2011, 22: 1824-1827. 10.1093/annonc/mdq695.CrossRefPubMed
52.
Hsing AW, Chua S, Gao YT, Gentzschein E, Chang L, Deng J, Stanczyk FZ: Prostate cancer risk and serum levels of insulin and leptin: a population-based study. J Natl Cancer Inst. 2001, 93: 783-789. 10.1093/jnci/93.10.783.CrossRefPubMed
53.
Pollak M: Insulin-like growth factors and prostate cancer. Epidemiol Rev. 2001, 23: 59-66. 10.1093/oxfordjournals.epirev.a000796.CrossRefPubMed
54.
55.
Wallner LP, Morgenstern H, McGree ME, Jacobson DJ, St Sauver JL, Jacobsen SJ, Sarma AV: The effects of metabolic conditions on prostate cancer incidence over 15 years of follow-up: results from the Olmsted County Study. BJU Int. 2011, 107: 929-935. 10.1111/j.1464-410X.2010.09703.x.CrossRefPubMed
56.
57.
De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK: The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012, 61: 560-570. 10.1016/j.eururo.2011.11.013.CrossRefPubMed
58.
Vucenik I, Stains JP: Obesity and cancer risk: evidence, mechanisms, and recommendations. Ann N Y Acad Sci. 2012, 1271: 37-43. 10.1111/j.1749-6632.2012.06750.x.CrossRefPubMedPubMedCentral
59.
Jacobs EJ, Gapstur SM: Cholesterol and cancer: answers and new questions. Cancer Epidemiol Biomark Prev. 2009, 18: 2805-2806. 10.1158/1055-9965.EPI-09-1027.CrossRef
60.
Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL: Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol. 2008, 168: 250-260. 10.1093/aje/kwn141.CrossRefPubMedPubMedCentral
61.
Bansal D, Undela K, D’Cruz S, Schifano F: Statin use and risk of prostate cancer: a meta-analysis of observational studies. PLoS One. 2012, 7: e46691-10.1371/journal.pone.0046691.CrossRefPubMedPubMedCentral
62.
Platz EA, Till C, Goodman PJ, Parnes HL, Figg WD, Albanes D, Neuhouser ML, Klein EA, Thompson IM, Kristal AR: Men with low serum cholesterol have a lower risk of high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomark Prev. 2009, 18: 2807-2813. 10.1158/1055-9965.EPI-09-0472.CrossRef
63.
Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC: Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA. 1992, 89: 3367-3371. 10.1073/pnas.89.8.3367.CrossRefPubMedPubMedCentral
64.
65.
Cussenot O, Valeri A: Heterogeneity in genetic susceptibility to prostate cancer. Eur J Intern Med. 2001, 12: 11-16. 10.1016/S0953-6205(00)00136-9.CrossRefPubMed
66.
Rebbeck TR: Inherited genotype and prostate cancer outcomes. Cancer Epidemiol Biomark Prev. 2002, 11 (10 Pt 1): 945-952.
67.
Schaid DJ: The complex genetic epidemiology of prostate cancer. Hum Mol Genet. 2004, 13: R103-R121. 10.1093/hmg/ddh072.CrossRefPubMed
68.
Rybicki BA, Ph D, Neslund-dudas C, Nock NL, Schultz LR, Eklund L, Rosbolt J, Bock CH, Monaghan KG: Prostate cancer risk from occupational exposure to polycyclic aromatic hydrocarbons interacting with the GSTP1 Ile105Val polymorphism. Cancer Detect Prev. 2006, 30 (5): 412-422. 10.1016/j.cdp.2006.09.004.CrossRefPubMedPubMedCentral
69.
Zhu Y, Zheng T, Stevens RG, Zhang Y, Boyle P: Does “clock” matter in prostate cancer?. Cancer Epidemiol Biomark Prev. 2006, 15: 3-5. 10.1158/1055-9965.EPI-05-0631.CrossRef
70.
Golden R, Kimbrough R: Weight of evidence evaluation of potential human cancer risks from exposure to polychlorinated biphenyls: an update based on studies published since 2003. Crit Rev Toxicol. 2009, 39: 299-331. 10.1080/10408440802291521.CrossRefPubMed
71.
Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL: Testing the circadian gene hypothesis in prostate cancer: a population-based case–control study. Cancer Res. 2009, 69: 9315-9322. 10.1158/0008-5472.CAN-09-0648.CrossRefPubMedPubMedCentral
72.
Chu LW, Zhu Y, Yu K, Zheng T, Chokkalingam AP, Stanczyk FZ, Gao Y-T, Hsing AW: Correlation between circadian gene variants and serum levels of sex steroids and insulin-like growth factor-I. Cancer Epidemiol Biomark Prev. 2008, 17: 3268-3273. 10.1158/1055-9965.EPI-08-0073.CrossRef
73.
Villers A, Malavaud B, Rebillard X, Bataille V, Iborra F: ERSPC: features and preliminary results of France. BJU Int. 2003, 92 (Suppl 2): 27-29.CrossRefPubMed
74.
Schröder FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Páez A, Määttänen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, Van der Kwast T, Kujala PM, Blijenberg BG, Stenman U-H, Huber A, Taari K, Hakama M, Moss SM, De Koning HJ, Auvinen A: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med. 2012, 366: 981-990. 10.1056/NEJMoa1113135.CrossRefPubMed
75.
European Foundation for the Improvement of living and Working Conditions: Fourth European Working Conditions Survey. 2007, Luxembourg: Office for Official Publications of the European Communities
76.
Spitz MR, Wu X, Mills G: Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol. 2005, 23: 267-275. 10.1200/JCO.2005.05.122.CrossRefPubMed
77.
Spitz MR, Caporaso NE, Sellers TA: Integrative cancer epidemiology–the next generation. Cancer Discov. 2012, 2: 1087-1090. 10.1158/2159-8290.CD-12-0424.CrossRefPubMedPubMedCentral
Metadata
Title
Epidemiological study of prostate cancer (EPICAP): a population-based case–control study in France
Authors
Florence Menegaux
Antoinette Anger
Hasina Randrianasolo
Claire Mulot
Pierre Laurent-Puig
François Iborra
Jean-Pierre Bringer
Benoit Leizour
Rodolphe Thuret
Pierre-Jean Lamy
Xavier Rébillard
Brigitte Trétarre
EPICAP Study Group
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-106

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Clinical characteristics and prognostic factors of bone lymphomas: focus on the clinical significance of multifocal bone involvement by primary bone large B-cell lymphomas

Research article

MicroRNA-1246 enhances migration and invasion through CADM1 in hepatocellular carcinoma

Research article

A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

Research article

RETRACTED ARTICLE: Identification of novel signaling components in N,N’-Dinitrosopiperazine-mediated metastasis of nasopharyngeal Carcinoma by quantitative phosphoproteomics

Research article

Immunohistochemical determination of the miR-1290 target arylamine N-acetyltransferase 1 (NAT1) as a prognostic biomarker in breast cancer

Research article

Adherence to hormone therapy among women with breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits